Coherus BioSciences, Inc. ("Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback